R
Raghu Kalluri
Researcher at University of Texas MD Anderson Cancer Center
Publications - 325
Citations - 89851
Raghu Kalluri is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Angiogenesis. The author has an hindex of 115, co-authored 306 publications receiving 71127 citations. Previous affiliations of Raghu Kalluri include Beth Israel Deaconess Medical Center & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties
TL;DR: The two distinct RGD-independent binding sites on tumstatin suggest unique αvβ3 integrin-mediated mechanisms governing the two distinct anti-tumor properties of tumStatin.
Journal ArticleDOI
Clinical and therapeutic relevance of cancer-associated fibroblasts.
TL;DR: In this paper, the clinical relevance of CAFs is summarized with an emphasis on their value as prognosis factors and therapeutic targets, including how these complex bimodal functions evolve and are subjugated by neoplastic cells.
Journal ArticleDOI
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
Hiroyasu Tsukaguchi,Akulapalli Sudhakar,Tu Cam Le,Trang Nguyen,Jun Yao,Joshua A. Schwimmer,Asher D. Schachter,Esteban Poch,Patrícia Ferreira Abreu,Gerald B. Appel,Aparecido B. Pereira,Raghu Kalluri,Martin R. Pollak +12 more
TL;DR: R229Q appears to enhance susceptibility to FSGS in association with a second mutant NPHS2 allele, which may define a subgroup of FSGS patients unresponsive to corticosteroids.
Journal ArticleDOI
Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.
Yohei Maeshima,Mark Manfredi,Corinne L. Reimer,Kathryn A. Holthaus,Helmut Hopfer,Babi R. Chandamuri,Surender Kharbanda,Raghu Kalluri +7 more
TL;DR: In vivo studies demonstrate that Tum-5, a domain derived from tumstatin, is an effective inhibitor of tumor-associated angiogenesis and a promising candidate for the treatment of cancer and suggest that through the action of endogenous inhibitors, αvβ3 integrin may also function as a negative regulator of angiogenic.
Journal ArticleDOI
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing
Sonia A. Melo,Alberto Villanueva,Catia Moutinho,Veronica Davalos,Riccardo Spizzo,Cristina Ivan,Simona Rossi,Fernando Setien,Oriol Casanovas,Laia Simó-Riudalbas,Javier Carmona,Jordi Carrere,August Vidal,Alvaro Aytes,Sara Puertas,Santiago Ropero,Raghu Kalluri,Carlo M. Croce,George A. Calin,Manel Esteller +19 more
TL;DR: The small molecule enoxacin, a fluoroquinolone used as an antibacterial compound, enhances the production of miRNAs with tumor suppressor functions by binding to the miRNA biosynthesis protein TAR RNA-binding protein 2 (TRBP).